Cell Death and Disease (Jun 2021)

Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index

  • Adrien Joseph,
  • Hui Chen,
  • Gerasimos Anagnostopoulos,
  • Léa Montégut,
  • Antoine Lafarge,
  • Omar Motiño,
  • Maria Castedo,
  • Maria Chiara Maiuri,
  • Karine Clément,
  • Safae Terrisse,
  • Anne Laure Martin,
  • Ines Vaz-Luis,
  • Fabrice Andre,
  • Franziska Grundler,
  • Françoise Wilhelmi de Toledo,
  • Frank Madeo,
  • Laurence Zitvogel,
  • François Goldwasser,
  • Benoit Blanchet,
  • Frédéric Fumeron,
  • Ronan Roussel,
  • Isabelle Martins,
  • Guido Kroemer

DOI
https://doi.org/10.1038/s41419-021-03864-9
Journal volume & issue
Vol. 12, no. 6
pp. 1 – 14

Abstract

Read online

Abstract In mice, the plasma concentrations of the appetite-stimulatory and autophagy-inhibitory factor acyl-coenzyme A binding protein (ACBP, also called diazepam-binding inhibitor, DBI) acutely increase in response to starvation, but also do so upon chronic overnutrition leading to obesity. Here, we show that knockout of Acbp/Dbi in adipose tissue is sufficient to prevent high-fat diet-induced weight gain in mice. We investigated ACBP/DBI plasma concentrations in several patient cohorts to discover a similar dual pattern of regulation. In relatively healthy subjects, ACBP/DBI concentrations independently correlated with body mass index (BMI) and age. The association between ACBP/DBI and BMI was lost in subjects that underwent major weight gain in the subsequent 3–9 years, as well as in advanced cancer patients. Voluntary fasting, undernutrition in the context of advanced cancer, as well as chemotherapy were associated with an increase in circulating ACBP/DBI levels. Altogether, these results support the conclusion that ACBP/DBI may play an important role in body mass homeostasis as well as in its failure.